Liu Zi-Xuan, Liu Xiao-Yan, Tan Wei-Wei, Zhang Wei-Bing, Zhang Ya-Li, Zheng Lie, Dai Yan-Cheng
Department of Gastroenterology, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200082, China.
Institute of Digestive Diseases, Long Hua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
Contemp Clin Trials Commun. 2024 Dec 5;42:101409. doi: 10.1016/j.conctc.2024.101409. eCollection 2024 Dec.
Ulcerative colitis (UC) is a chronic non-specific inflammatory intestinal disease, categoried under "dysentery" and "intestinal bleeding" in Traditional Chinese Medicine (TCM). Jianpi Qingchang decoction (JPQC) is a combination formula specifically designed for the treatment of UC. The primary objective of this study is to examine the clinical efficacy of JPQC in individuals diagnosed with UC who exhibit both spleen deficiency and dampness-heat syndrome, along with the presence of fatigue. The investigation will focus on assessing the impact of JPQC on the gut microbiota and metabolites in these patients, aiming to elucidate the regulatory mechanism that JPQC exerts on the gut microbiota and metabolites in the context of UC-related fatigue.
In this randomized clinical trial, 140 subjects diagnosed with UC will be recruited and randomized into two groups. They will receive either JPQC combined with mesalazine or mesalazine alone for 12 weeks. Follow-up visits will be conducted every four weeks, with a post-treatment visit scheduled at 6 months. The primary outcome measures include the Inflammatory bowel disease fatigue scale(IBD-F). Secondary efficacy indicators comprise the assessment of TCM syndrome and individual syndrome efficacy before and after treatment, Modified Mayo score, Simple clinical colitis activity index (SCCAI), as well as the Inflammatory Bowel Disease Questionnaire (IBDQ) for each group. The other outcomes are the Intestinal microbial diversity and non-targeted metabonomics, which will be measured at baseline and 12 weeks after randomization.
If effective, JPQC will provide substantial clinical evidence concerning the effectiveness and safety in the treatment of patients with UC experiencing spleen deficiency and dampness-heat syndrome accompanied by fatigue.
ChiCTR2300068348.
溃疡性结肠炎(UC)是一种慢性非特异性炎症性肠病,在中医中归属于“痢疾”“便血”范畴。健脾清肠汤(JPQC)是专门用于治疗UC的复方制剂。本研究的主要目的是探讨JPQC对诊断为UC且表现为脾虚湿热证并伴有疲劳的患者的临床疗效。研究将重点评估JPQC对这些患者肠道微生物群和代谢物的影响,旨在阐明JPQC在UC相关疲劳背景下对肠道微生物群和代谢物的调节机制。
在这项随机临床试验中,将招募140名诊断为UC的受试者并随机分为两组。他们将接受JPQC联合美沙拉嗪或单独使用美沙拉嗪治疗12周。每四周进行一次随访,在6个月时安排一次治疗后随访。主要结局指标包括炎症性肠病疲劳量表(IBD-F)。次要疗效指标包括治疗前后中医证候及单项证候疗效评估、改良梅奥评分、简易临床结肠炎活动指数(SCCAI)以及每组的炎症性肠病问卷(IBDQ)。其他结局是肠道微生物多样性和非靶向代谢组学,将在随机分组后的基线和12周时进行测量。
如果有效,JPQC将为治疗伴有疲劳的脾虚湿热证UC患者的有效性和安全性提供大量临床证据。
ChiCTR2300068348。